Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 1/2 1

Status

Active not recruiting 2Unknown 1Recruiting 1Enrolling by invitation 1Completed 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 4Observational 2

Sponsor

Cancer Type

Breast 6

Conditions

Breast Neoplasms 6Carcinoma, Non-Small-Cell Lung 4Recurrence 3Pancreatic Neoplasms 3Neoplasms 3Neoplasm Metastasis 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Uterine Cervical Neoplasms 1Tracheal Diseases 1Smoking Cessation 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Salivary Gland Neoplasms 1Rhabdomyosarcoma 1Peritoneal Neoplasms 1Pain, Postoperative 1Ovarian Neoplasms 1Neurofibrosarcoma 1Neuroblastoma 1Neoplasms, Plasma Cell 1Mucopolysaccharidosis I 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, Large B-Cell, Diffuse 1Lymphedema 1Lung Neoplasms 1Locally Advanced Rectal Cancer 1

Interventions

Trastuzumab 628Paclitaxel 577Cyclophosphamide 555Docetaxel 485Capecitabine 401Letrozole 376Fulvestrant 327Doxorubicin 294Carboplatin 279Tamoxifen 275Anastrozole 243exemestane 228Radiotherapy 218Epirubicin 211Bevacizumab 196palbociclib 189pertuzumab 186Vinorelbine 167Lapatinib 167Gemcitabine 166pembrolizumab 162Surveys and Questionnaires 138Exercise 136Magnetic Resonance Spectroscopy 123Fluorouracil 119Blood Specimen Collection 118eribulin 117Albumin-Bound Paclitaxel 117Drug Therapy 111130-nm albumin-bound paclitaxel 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Breast Neoplasms × Combined Modality Therapy × Clear all
NCT07018427 2025-06-12

Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer

Peking University Cancer Hospital & Institute

Active not recruiting
70 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06793306 2025-02-14

A Study Comparing the Differences Between Young and Non-young Breast Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Enrolling by invitation
3,000 enrolled
Breast

Breast Neoplasms

NCT05228951 2022-09-13

Pyrotinib Maleate, Trastuzumab, SHR6390 and Letrozole in Combination for Stage II-III TPBC

Shengjing Hospital

Phase 2 Recruiting
12 enrolled
Breast

Breast Neoplasms

NCT04486911 2022-08-02

Pyrotinib Maleate, CDK4/6 Inhibitor and Letrozole in Combination for Stage II-III TPBC: a Phase II Trial

Shengjing Hospital

Phase 2 Active not recruiting
89 enrolled
Breast

Breast Neoplasms

NCT03411161 2021-05-25

S 81694 Plus Paclitaxel in Metastatic Breast Cancer

Servier

Phase 1/2 Completed
22 enrolled
Breast

Breast Neoplasms, Mucopolysaccharidosis I, Triple Negative Breast Neoplasms

NCT02165696 2014-06-17

LYMPHATIC

University of Malaga

Phase NA Unknown
44 enrolled
Breast

Breast Neoplasms, Lymphedema

Data powered by HemOnc (CC BY 4.0) Colophon âš¡